about usexecutive managementboard of directorscontact ustechnology & pipelinetargetsimmtac engineeringimmtacs in actioninformation for patientsclinicalpipelinepublicationspartneringnews & eventscareers breaking new ground in immuno oncology breaking new ground in immuno oncology immunocore immunocore is a world leading biotechnology company focused on the development of a new class of immunotherapeutic drugs based on proprietary t cell receptor tcr technology . the company is focusing its technology primarily in the area of immuno oncology via the immtac platform . the same underlying technology is being extended to address other hard to treat conditions including viral infections through the immtav platform and autoimmune diseases . the scientific expertise at immunocore spans the entire process of drug development . from the discovery and validation of suitable disease targets through to the design and engineering of immune activating tcr based reagents to preclinical and clinical assessment . latest news oct 12 2016 immunocore appoints paul fry as chief financial officer sep 12 2016 immunocore ranked in the sunday times hiscox tech track 100 sep 07 2016 immunocore wins private uk life science company of the year at biotech and money assembly and awards . view all news discovery and validation of novel disease targets learn more immtacs redefining immuno oncology through tcr targeted t cell redirection learn more immtacs in the clinic delivering better tomorrows learn more immtacs in action immunocore limited 101 park drive milton park abingdon oxon ox14 4ry uk t 44 0 1235 438600 e info immunocore.com 2016 immunocore . immunocore immtac and immtav are trademarks of immunocore ltd about immunocoretechnology & pipelinepartneringnews & eventscareers